Hepatitis C

Top Story

Funding for medical research and public health must reflect reality

Funding for medical research and public health must reflect reality
Infectious Disease News, July 2017
William Powderly, MD

The last few years have seen a growing force of infectious disease challenges that together pose an unprecedented range of threats to health here in the United States and in countries around the world where Americans travel and conduct business. While outbreaks of Ebola, Zika, SARS and MERS have spread from their places of origin with devastating impacts, rising rates of resistance to antimicrobial drugs threaten the gains of modern medicine at home and globally. New and re-emerging diseases with pandemic potential continue to surface, and diseases that include tuberculosis, once considered all but conquered, have evolved faster than the medicines to control them, to pose new dangers.

The Infectious Diseases Society of America, the oldest and largest association of physicians, scientists and other health care professionals specializing in preventing and treating transmissible illnesses, has recognized these threats. We have worked for more than a decade to raise awareness that antibiotic development is falling far short of need, and urged accelerated and immediate action in research, education, training, evidence-based practice and informed medical stewardship to improve our capacities to detect, prevent and respond to infectious diseases at home and abroad. We recognize that when medical research lags, pathogens gain ground, and that in an increasingly connected world, we cannot afford the costs that infections that are not countered by effective interventions inflict on families and communities, on individual and public health. And we are concerned because the budget proposal released by the Trump administration for the coming fiscal year does not reflect recognition of any of these realities.

In the Journals

HCV rates climbing in younger HIV-positive MSM

July 20, 2017
Hepatitis C infection rates continue to increase in Northern Europe in recent years among younger men who have HIV and have sex with men, with those more recently…

FDA approves Vosevi for HCV

July 18, 2017
FDA announced the approval of Vosevi for the treatment of adults with chronic hepatitis C genotypes 1 through 6, according to an agency press release…
In the Journals

New EHR alert increases HCV screening among baby boomers

July 18, 2017
Implementation of an electronic health record-based prompt significantly increased hepatitis C screening rates among baby boomers in primary care. According to the…
More Headlines »
CME

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
Editorial

Funding for medical research and public health must reflect reality

Infectious Disease News, July 2017
William Powderly, MD
The last few years have seen a growing force of infectious disease challenges that together pose an unprecedented range…
More »
Resource Centers
ASM Microbe

ASM Microbe

Video
Meeting News

VIDEO: HCV elimination requires equitable care for injection drug users

April 19, 2017
More »
Advertisement
Advertisement